{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T20:23:35Z","timestamp":1749414215533},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cld.2013.07.007","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T06:45:24Z","timestamp":1378277124000},"page":"657-670","source":"Crossref","is-referenced-by-count":2,"title":["Antiretroviral and Anti\u2013Hepatitis C Virus Direct-Acting Antiviral-Related Hepatotoxicity"],"prefix":"10.1016","volume":"17","author":[{"given":"Hyosun","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Martel-Laferriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1310\/hct1304-189","article-title":"Renal toxicity associated with antiretroviral therapy","volume":"13","author":"Calza","year":"2012","journal-title":"HIV Clin Trials"},{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib2","first-page":"359","article-title":"Antiretroviral molecules and cardiovascular diseases","volume":"35","author":"Gibellini","year":"2012","journal-title":"New Microbiol"},{"issue":"2","key":"10.1016\/j.cld.2013.07.007_bib3","first-page":"67","article-title":"Analysis of neuropsychiatric adverse events during clinical trials of efavirnenz in antiretroviral-na\u00efve patients: a systematic review","volume":"12","author":"Gazzard","year":"2010","journal-title":"AIDS Rev"},{"issue":"12","key":"10.1016\/j.cld.2013.07.007_bib4","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MEG.0b013e328305b9e0","article-title":"Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis","volume":"20","author":"Akhtar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2013.07.007_bib5","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00126334-200309011-00006","article-title":"Managing antiretroviral associated liver disease","volume":"34","author":"Dieterich","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cld.2013.07.007_bib6","series-title":"Table\u00a0of grading severity of adult adverse experiences","author":"AIDS Clinical Trials Group","year":"1996"},{"key":"10.1016\/j.cld.2013.07.007_bib7","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis","year":"2003","journal-title":"AIDS Rev"},{"issue":"15","key":"10.1016\/j.cld.2013.07.007_bib8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/00002030-200310170-00009","article-title":"Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment","volume":"17","author":"de Maat","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2013.07.007_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1086\/313921","article-title":"Hyperlactemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors","volume":"31","author":"Brinkman","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2013.07.007_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1567-7249(02)00003-X","article-title":"Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?","volume":"1","author":"Dagan","year":"2002","journal-title":"Mitochondrion"},{"key":"10.1016\/j.cld.2013.07.007_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00002030-200104130-00016","article-title":"Management of hyperlactatemia: no need for routine lactate measurements","volume":"15","author":"Brinkman","year":"2001","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.cld.2013.07.007_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0300-2977(00)00064-4","article-title":"Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient","volume":"57","author":"Bleeker-Rovers","year":"2000","journal-title":"Neth J Med"},{"issue":"2","key":"10.1016\/j.cld.2013.07.007_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0032-1316473","article-title":"The burden of liver disease in human immunodeficiency virus-infected patients","volume":"32","author":"Puoti","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib14","first-page":"61","article-title":"Noncirrhotic portal hypertension associated with didanosine: a case report and literature review","volume":"65","author":"Chang","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/COH.0b013e3283473405","article-title":"Influence of antiretroviral therapy on liver disease","volume":"6","author":"Kovari","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/QCO.0b013e3283420f08","article-title":"Noncirrhotic portal hypertension in HIV infection","volume":"24","author":"Vispo","year":"2011","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"10.1016\/j.cld.2013.07.007_bib17","first-page":"697","article-title":"Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature","volume":"24","author":"Cesari","year":"2010","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.cld.2013.07.007_bib18","doi-asserted-by":"crossref","first-page":"S945","DOI":"10.1016\/S0016-5085(12)63664-6","article-title":"Noncirrhotic portal hypertension in HIV-infected patients: a case control study","volume":"142","author":"Parikh","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"Rivero","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cld.2013.07.007_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.cld.2013.07.007_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002030-200201250-00020","article-title":"Liver toxicity caused by nevirapine","volume":"16","author":"Gonzalez de Requena","year":"2002","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.cld.2013.07.007_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1468-1293.2010.00873.x","article-title":"Nevirapine-associated hepatotoxicity was not predicted by CD4 count\u2265250 cells\/\u03bcL among women in Zambia, Thailand and Kenya","volume":"11","author":"Peters","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.cld.2013.07.007_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of Hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2013.07.007_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/jis690","article-title":"Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir boosted atazanavir in AIDS Clinical Trials Group Study A5202","volume":"207","author":"Ribaudo","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib26","first-page":"641","article-title":"Review of tipranavir in the treatment of drug-resistant HIV","volume":"3","author":"Streeck","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cld.2013.07.007_bib27","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: aidsinfo.nih.gov\/guidelines. Accessed March 3, 2013."},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity observed in clinical trials of Aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.cld.2013.07.007_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-2036.2007.03307.x","article-title":"Review article: drug hepatotoxicity","volume":"25","author":"Chang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2013.07.007_bib30","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study","volume":"6","author":"Eyster","year":"1993","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus\u00a0infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study","volume":"38","author":"Martin-Carbonero","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.cld.2013.07.007_bib34","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.cld.2013.07.007_bib35","first-page":"190","article-title":"Liver and kidney transplantation in HIV-infected patients","volume":"11","author":"Tan-Tam","year":"2009","journal-title":"AIDS Rev"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity","volume":"52","author":"Nunez","year":"2010","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.cld.2013.07.007_bib38","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/00002030-200411050-00008","article-title":"Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV\/hepatitis C virus co-infected patients","volume":"18","author":"Marin\u00e9-Barjoan","year":"2004","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.cld.2013.07.007_bib39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"Labarga","year":"2007","journal-title":"J\u00a0Infect Dis"},{"issue":"9","key":"10.1016\/j.cld.2013.07.007_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.cld.2013.07.007_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","article-title":"Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV\/HCV-coinfected patients","volume":"18","author":"Medrano","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3851\/IMP1992","article-title":"Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain","volume":"17","author":"Poveda","year":"2012","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1016\/j.cld.2013.07.007_bib43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","article-title":"Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV\/HIV-coinfected patients","volume":"11","author":"Barreiro","year":"2006","journal-title":"Antivir Ther"},{"issue":"17","key":"10.1016\/j.cld.2013.07.007_bib44","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/01.aids.0000247583.38943.95","article-title":"Regression of liver fibrosis in hepatitis C virus\/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin","volume":"20","author":"Soriano","year":"2006","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.cld.2013.07.007_bib45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/135965350400900616","article-title":"Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.cld.2013.07.007_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","article-title":"Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"50","author":"Berenguer","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2013.07.007_bib47","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: aidsinfo.nih.gov\/guidelines. Accessed February 23, 2013."},{"issue":"13","key":"10.1016\/j.cld.2013.07.007_bib48","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","article-title":"Risk factors for symptomatic mitochondrial toxicity in HIV\/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy","volume":"40","author":"Bani-Sadr","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.cld.2013.07.007_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0032-1316469","article-title":"Management and treatment of chronic hepatitis C in HIV patients","volume":"32","author":"Barreiro","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2013.07.007_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2893.2009.01261.x","article-title":"Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance","volume":"18","author":"Blanco","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2013.07.007_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.22665","article-title":"Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy","volume":"49","author":"Ingiliz","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.cld.2013.07.007_bib54","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1086\/605676","article-title":"Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients","volume":"49","author":"Pineda","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2013.07.007_bib55","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1086\/313842","article-title":"Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus","volume":"30","author":"Sulkowski","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"9397","key":"10.1016\/j.cld.2013.07.007_bib56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2013.07.007_bib57","unstructured":"Victrelis (boceprevir) [2011]. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf. Accessed February 26, 2013."},{"key":"10.1016\/j.cld.2013.07.007_bib58","unstructured":"Incivek (telaprevir) [2011]. Available at: http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf. Accessed February 26, 2013."},{"key":"10.1016\/j.cld.2013.07.007_bib59","unstructured":"Xu K. Pharmasset's PSI938 discontinued; impact on other nukes in hepatitis C? Wm Blair & Co Analyst Equity Research Report. Available at: www.natap.org\/2011\/HCV\/121711_02.htm. Accessed March 26, 2013."},{"key":"10.1016\/j.cld.2013.07.007_bib60","unstructured":"Dieterich D, Soriano V, Shermann K, et\u00a0al. Telaprevir in combination with peginterferon alfa-2a\/ribavirin in HCV\/HIV co-infected patients: SVR12 interim analysis. Presented at the19th Conference on Retrovirus and Opportunistic Infections. Seattle, March 5\u20138, 2012. Abstract 46."},{"key":"10.1016\/j.cld.2013.07.007_bib61","unstructured":"Van Heeswijk R, Vandevoorde A, Boogaerts G, et\u00a0al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27\u2013March 2, 2011. Abstract 119."},{"key":"10.1016\/j.cld.2013.07.007_bib62","unstructured":"Van Heeswijk R, Gard V, Boogaerts G, et\u00a0al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17\u201320, 2011. Abstract A1\u20131738a."},{"issue":"3","key":"10.1016\/j.cld.2013.07.007_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cld.2013.07.007_bib64","unstructured":"de Kanter CT, Blonk MI, Colbers AP, et\u00a0al. Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir. Presented at the 19th Conference on Retroviruses and Opportunistic Infections; Seattle, March 6, 2012. Abstract 772LB."},{"key":"10.1016\/j.cld.2013.07.007_bib65","unstructured":"Kassera C, Hughes E, Treitel M, et\u00a0al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27\u2013March 2, 2011. Abstract 118."},{"key":"10.1016\/j.cld.2013.07.007_bib66","doi-asserted-by":"crossref","unstructured":"Hulskotte EG, Feng HP, Xuan F, et\u00a0al. Pharmacokinetic Interaction between the\u00a0HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Presented at the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5\u20138, 2011. Abstract 47.","DOI":"10.1093\/cid\/cis968"},{"key":"10.1016\/j.cld.2013.07.007_bib67","unstructured":"Kirby B, Mathias A, Rossi S, et\u00a0al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir\/ritonavir, or raltegravir in healthy volunteers. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9\u201313, 2012. Abstract 1877."},{"key":"10.1016\/j.cld.2013.07.007_bib68","unstructured":"Douglas DJ, Rockstroh K, Orkin C, et\u00a0al. Simeprevir (TMC435) with peginterferon\/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: week-24 interim analysis of the TMC435-C212 study. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3\u20136, 2013. Oral abstract 154LB."},{"key":"10.1016\/j.cld.2013.07.007_bib69","unstructured":"Bifano M, Hwang C, Oosterhuis B, et\u00a0al. Assessment of HIV ARV Drug Interactions with the HCV NS5A Replication Complex Inhibitor BMS-790052 Demonstrates a Pharmacokinetic Profile which Supports Co-administration with Tenofovir Disoproxil Fumarate, Efavirenz, and Atazanavir\/ritonavir. Presented at the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5\u20138, 2012. Abstract 618."},{"key":"10.1016\/j.cld.2013.07.007_bib70","unstructured":"Dieterich D, Soriano V, Nelson M, et\u00a0al. STARTVerso 4: high rates of early virologic response in HCV genotype 1\/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3\u20136, 2013. Oral abstract 40LB."},{"key":"10.1016\/j.cld.2013.07.007_bib71","unstructured":"Sabo JP, Kort J, Haschke M, et\u00a0al. Pharmacokinetic interactions of darunavir\/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3\u20136, 2013. Oral abstract 35."},{"key":"10.1016\/j.cld.2013.07.007_bib72","unstructured":"Sulkowski M, Pol S, Cooper C, et\u00a0al. Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co-infected patients. Presented at the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5\u20138, 2011. Abstract 47."}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326113000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326113000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T09:07:11Z","timestamp":1688461631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326113000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1089326113000366"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2013.07.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}